|
|
|
Three main aspects are covered
The main issue is to calculate the cumulative activity for Kr81m and for Tc99m-MAA in the lungs ie the area under the activity-time curves.
The ICRP model for Kr81m assumes that all the Kr81m activity stays in the lungs ie only decay is assumed. They calculate effective dose values in units of mSv/MBq.s and give the following information.
We have developed a very simple model of the Kr81m administration process. Unlike the ICRP model this takes account of the fact that the patient also breathes out, loosing Kr81m in the process.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Last modified: November 29, 2002 |